Verrica Pharmaceuticals Inc (NASDAQ:VRCA) — Market Cap & Net Worth
Market Cap & Net Worth: Verrica Pharmaceuticals Inc (VRCA)
Verrica Pharmaceuticals Inc (NASDAQ:VRCA) has a market capitalization of $103.07 Million ($103.07 Million) as of June 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #19164 globally and #4361 in its home market, demonstrating a 0.17% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Verrica Pharmaceuticals Inc's stock price $6.00 by its total outstanding shares 17178786 (17.18 Million). Review Verrica Pharmaceuticals Inc debt and liabilities to assess the company's total debt and financial obligations.
Verrica Pharmaceuticals Inc Market Cap History: 2018 to 2026
Verrica Pharmaceuticals Inc's market capitalization history from 2018 to 2026. Data shows change from $140.01 Million to $103.07 Million (-12.51% CAGR).
Index Memberships
Verrica Pharmaceuticals Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.43 Trillion | 0.00% | #543 of 976 |
|
NASDAQ Composite
IXIC
|
$41.27 Trillion | 0.00% | #1866 of 3165 |
Weight: Verrica Pharmaceuticals Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Verrica Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Verrica Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
4.01x
Verrica Pharmaceuticals Inc's market cap is 4.01 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $197.73 Million | $12.00 Million | -$45.50 Million | 16.48x | N/A |
| 2021 | $157.36 Million | $12.00 Million | -$35.08 Million | 13.11x | N/A |
| 2022 | $47.24 Million | $9.03 Million | -$24.49 Million | 5.23x | N/A |
| 2023 | $125.75 Million | $5.12 Million | -$67.00 Million | 24.54x | N/A |
| 2024 | $12.03 Million | $7.57 Million | -$76.58 Million | 1.59x | N/A |
| 2025 | $142.76 Million | $35.58 Million | -$17.89 Million | 4.01x | N/A |
Competitor Companies of VRCA by Market Capitalization
Companies near Verrica Pharmaceuticals Inc in the global market cap rankings as of June 18, 2026.
Key companies related to Verrica Pharmaceuticals Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #442 globally with a market cap of $63.33 Billion USD.
- UCB SA (BR:UCB): Ranked #550 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #574 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $453.17 |
| #442 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $63.33 Billion | $614.73 |
| #550 | UCB SA | BR:UCB | $49.68 Billion | €250.00 |
| #574 | Argen-X | BR:ARGX | $47.14 Billion | €755.80 |
Verrica Pharmaceuticals Inc Historical Marketcap From 2018 to 2026
Between 2018 and today, Verrica Pharmaceuticals Inc's market cap moved from $140.01 Million to $ 103.07 Million, with a yearly change of -12.51%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $103.07 Million | -27.80% |
| 2025 | $142.76 Million | +1087.14% |
| 2024 | $12.03 Million | -90.44% |
| 2023 | $125.75 Million | +166.18% |
| 2022 | $47.24 Million | -69.98% |
| 2021 | $157.36 Million | -20.42% |
| 2020 | $197.73 Million | -27.56% |
| 2019 | $272.97 Million | +94.97% |
| 2018 | $140.01 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of Verrica Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $103.07 Million USD |
| MoneyControl | $103.07 Million USD |
| MarketWatch | $103.07 Million USD |
| marketcap.company | $103.07 Million USD |
| Reuters | $103.07 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Verrica Pharmaceuticals Inc
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the tr… Read more